Skip to main content
Premium Trial:

Request an Annual Quote

Northrop Grumman to Receive up to $27M in NIAID Funding to Head Bioinformatics Resource Centers

NEW YORK (GenomeWeb) – Northrop Grumman said on Thursday that the National Institute of Allergy and Infectious Diseases has chosen the company to head a team for the Bioinformatics Resource Centers for Infectious Diseases (BRC) contract.

The contract is for $4.9 million for the first year and will run through September 2019 for a total value of potentially $27 million. The award is a follow-on to the Virus Pathogen Resource/Influenza Research Database (IRD) BRC contract. In 2009, Northrop Grumman received $13 million in NIAID funding for the Bioinformatics Resource Centers, as Bioinform reported at the time.

Northrop Grumman will continue maintaining and enhancing the NIAID Bioinformatics Resource Center Virus websites as data repositories for genomic, proteomic, and other data associated with pathogenic viruses. They include influenza, Ebola, West Nile, severe acute respiratory syndrome and Middle East respiratory syndrome, enterovirus, pox, dengue, and hepatitis, the company said. It also will support an integrated analytics platform and tools for research directed at controlling and eliminating such pathogens.

A team led by Northrop Grumman, the J. Craig Venter Institute, and Vecna Technologies has managed the NIAID Virus BRC websites for the past five years and developed an integrated bioinformatics platform to support the development of vaccines, diagnostics, and therapeutics for pathogenic diseases, with a particular focus on influenza. Six scientists from the university research community will support the core team as co-investigators.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.